Burden of pneumococcal disease in children in Cuba before the introduction of a novel pneumococcal conjugate vaccine

Linares-Pérez, Nivaldo; Wahl, Brian; Rodríguez, Misladys; Toraño, Gilda; Toledo-Romaní, María Eugenia

doi:10.29392/joghr.3.e2019071

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-severe and severe NPNM cases were combined into one category. Pre-vaccination estimates from Linares et al were used to estimate the incidence and mortality rates for severe pneumonia, meningitis and NPNM caused by pneumococcus (Linares-Pérez et al, 2019). In the same study 1.8 non-severe pneumonia cases were reported for every 1.0 severe pneumonia case, so this ratio was used to calculate the incidence of non-severe pneumococcal pneumonia.…”

Section: Pneumococcal Disease Burden Inputsmentioning

confidence: 99%

Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme

Fariñas¹,

Linares-Pérez²,

Clark³

et al. 2020

International Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

To evaluate the cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban National Immunization Program (NIP). Methods: We compared PCV7-TT given at two, four and six months of age to a scenario without PCV7-TT, over a ten-year period (2020)(2021)(2022)(2023)(2024)(2025)(2026)(2027)(2028)(2029). We calculated the cost (Cuban pesos -CUP) per Disability Adjusted Life Year (DALY) averted from a Government perspective. We compared results from a static cohort model and a parsimonious prediction model informed by the serotype distribution among pneumococcal carriers and cases. We ran probabilistic and deterministic uncertainty analyses. Results: PCV7-TT could prevent 6897 (95% uncertainty interval, 4344-8750) hospitalizations and 189 (115-253) deaths in children <5 years of age, over the period 2020-2029. This could cost around 25 million (20-31) discounted CUP but would be offset by treatment cost savings of around 23 million (14-31). A parsimonious model predicted less favourable impact and cost-effectiveness but the cost per DALY averted was still less than 0.4 times the current GDP per capita. Conclusions: PCV7-TT is likely to be cost-effective in Cuba. The impact of the vaccine would need to be carefully monitored following its introduction into the NIP.

show abstract

Section: Pneumococcal Disease Burden Inputsmentioning

confidence: 99%

Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme

Fariñas¹,

Linares-Pérez²,

Clark³

et al. 2020

International Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

Burden of pneumococcal disease in children in Cuba before the introduction of a novel pneumococcal conjugate vaccine

Abstract: Back Background ground The Cuban heptavalent conjugate pneumococcal vaccine will be introduced for children beginning in 2020. We estimated the burden of pneumococcal cases and deaths in children 1-59 months in 2015.

Cited by 1 publication

References 14 publications

Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme

Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme

Contact Info

Product

Resources

About